The P.R.I.T.® lung model to test nanoparticle-based drugs

The German technology P.R.I.T.® with its air-liquid interface imitates lung behaviour. It is used for the first time to test a nanoparticle-based drug designed for inhalation.

Many studies require scientists to investigate effects of inhaled substances in lungs. One can think of studies related to smoking behaviors or urban pollution effects. Such studies are also needed for some drug development processes.  For example, the PneumoNP project develops a drug made for inhalation. Toxicity is tested also by investigating lung reactions under drug exposure.

There are several ways to forecast reaction of lungs to a substance without exposing humans. For example, animal models are used for clinical trials. Of course, ethical considerations encourage alternative methods to limit such in vivo tests. The Fraunhofer ITEM Institute in Hannover, Germany, developed an “in vitro model of lungs”. In 2017 and for the first time, this system, called P.R.I.T.®, will be used for testing nanoparticle-based drugs.

The P.R.I.T.® system belongs to the family of air-liquid interface setups. Basically, lung cells are placed on a membrane at the interface between the inhaled atmosphere and the culture medium that acts as blood input. These samples are exposed to a controlled test atmosphere containing the drug. Many parameters can be specifically defined like the composition of the air, the flow or even pressure. The great advantage of this technique is the almost-accurate replication of real-life lungs.

P.R.I.T.® air-liquid interface system principle and setup for the PneumoNP project

P.R.I.T.® air-liquid interface system principle and setup for the PneumoNP project

For the PneumoNP project, a nebulizer has been connected to the P.R.I.T.® system to test a drug made for inhalation. Scientists place human cells in the exposure unit and inject the nebulized drug in the air flow. The study aims to check the toxicity of the therapeutic formulation. Scientists are currently focussing on effects of the drug on lung cells and their genes. Using the P.R.I.T.® technology to test a nanoparticle-based drug is a premiere.

The Fraunhofer ITEM Institute is currently leading the study in their laboratory based in Hannover. First results will be publicly released by the end of the year. Beside the PneumoNP study, they use the P.R.I.T.® system within other projects for testing aerosols, particles and volatile organic compounds (VOCs).

 

__________________________________________________________________

Read more PneumoNP news

Major Classes of Antibiotics

Antibiotic resistance: Hope may come from small biotech companies

Discover Adenium, a small biotech company from Denmark. It develops the molecule that may become the next generation of antibiotics ...
Read More
Graphical abstract

New publication: Experimental methods for aerosol measurements in human airways

Experimental methods for flow and aerosol measurements in human airways and their replicas Abstract Recent developments in the prediction of ...
Read More
Meeting in Maastricht

PneumoNP: Exciting 6-month race ahead

With only six months to go before its end, the PneumoNP consortium gathered once more for their penultimate progress meeting ...
Read More